Red-hot generative AI specialist Insilico Medicine has teamed up with another major biopharma player, this time linking up ...
Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...
After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have ...
The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard of care for patients with breast cancer. The regulator is allowing ...
Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase ...
In the second of a new series of interviews with top executives from leading healthcare and comms agencies, Fierce Pharma ...
Insulet’s wearable insulin patch Omnipod may be able to seamlessly control insulin delivery for patients with diabetes, but ...
In an initiative to increase the efficiency of drug manufacturing in the United States, the FDA has proposed a streamlined ...
Even as the effort has met with fierce pushback from drugmakers, trade groups and opposition parties in the country’s own ...
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal cancer, the company’s Jemperli has met the main goal of a phase 2 trial, teeing up an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results